Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28129929 | 0.98 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL101880 | 0.98 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL17674561 | 0.95 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| Water SCHEMBL28249068 | 0.95 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL31059892 | 0.95 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL29375055 | 0.95 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL31153795 | 0.95 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2DRD1 | |
| Bromide SCHEMBL4290668 | 0.93 | CYP3A4 (0.46) | CYP3A4TDP1ESR1ESR2DRD1 | |
| Hydrochloric Acid SCHEMBL2126739 | 0.93 | CYP3A4 (0.46) | CYP3A4TDP1ESR1ESR2DRD1 | |
| SCHEMBL30015097 | 0.90 | CYP3A4 (0.42) | CYP3A4TDP1ESR1ESR2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024245193-A1 | HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-12-05 | — | — | WO | claimed |
| CN-117820333-A | KRAS G12C inhibitors | 伊莱利利公司 | 2024-04-05 | — | — | CN | claimed |
| EP-2176216-B1 | METHODS FOR SYNTHESIZING 9-SUBSTITUTED MINOCYCLINE | PARATEK PHARM INNC (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4514793-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024245193-A1 | HETEROAROMATIC RING COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024120419-A1 | FUSED TETRACYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024120433-A1 | FUSED CYCLIC COMPOUNDS AND USE THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024041573-A1 | FUSED MULTI-HETEROCYCLIC COMPOUNDS AS KRAS G12D MODULATORS AND USES THEREOF | ZAI LAB (SHANGHAI) CO., LTD. (CN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023209084-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| CN-114828964-A | KRAS G12C inhibitors | 伊莱利利公司 | 2022-07-29 | — | — | CN | disclosed |
| US-10788471-B2 | Determining stereoisomeric excess, concentration and absolute configuration | GEORGETOWN UNIVERSITY (US) | 2020-09-29 | — | — | US | disclosed |
| US-20180292370-A1 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | UNIV GEORGETOWN (US) | 2018-10-11 | — | — | US | disclosed |
| US-10012627-B2 | Determining stereoisomeric excess, concentration and absolute configuration | GEORGETOWN UNIVERSITY (US) | 2018-07-03 | — | — | US | disclosed |
| US-20160011156-A1 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | GEORGETOWN UNIVERSITY | 2016-01-14 | — | — | US | disclosed |
| WO-2014145251-A1 | DETERMINING STEREOISOMERIC EXCESS, CONCENTRATION AND ABSOLUTE CONFIGURATION | GEORGETOWN UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2176216-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | Paratek Pharmaceuticals, Inc. (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009009042-A1 | METHODS FOR SYNTHESIZING SUBSTITUTED TETRACYCLINE COMPOUNDS | PARATEK PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |